tiprankstipranks
Blurbs

Arvinas Holding Company (ARVN) Gets a Buy Rating from Leerink Partners

In a report issued on February 28, Christopher Liu from Leerink Partners initiated coverage with a Buy rating on Arvinas Holding Company (ARVNResearch Report) and a price target of $91.00. The company’s shares closed last Wednesday at $68.04.

According to TipRanks.com, Liu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.5% and a 15.0% success rate. Liu covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Nurix Therapeutics, and Cogent Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arvinas Holding Company with a $117.44 average price target, which is a 77.3% upside from current levels. In a report issued on February 14, BMO Capital also maintained a Buy rating on the stock with a $125.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $108.47 and a one-year low of $56.59. Currently, Arvinas Holding Company has an average volume of 484.9K.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Read More on ARVN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More